National Cancer Center – Tikaros, Convention on the Transfer of Technology for the Development of Immune Cancer Drugs

[아시아경제 박혜정 기자] The National Cancer Center announced on June 16 that it had entered into an exclusive licensing agreement for the development of an immunochemotherapy technology using genetically engineered T cells with biostatist Tikaros.

The patented technology for "T cells transfected with the mutant CTLA4 gene and their composition for anti-cancer immunotherapy" transferred to this agreement is an immunogenetic cell therapy technique developed by researchers at the National Cancer Center. In 2011, patent registration was completed in Japan and the United States last year. This technology is being evaluated as a new generation immune cell therapeutic technology that makes immune cells function in immune cells and makes them more immunotherapeutic.

Representative Lee Jae Won said, "This CTLA-4 technology gene transfer technology selectively acts on cancer-specific T cells, dramatically reducing side effects and dramatically improving efficacy. . " Professor Choi Kyung-ho of the Seoul National University, who is the original designer of this technology, said: "This is a unique concept of immune hyperactivity that does not exist. Has not been experienced anywhere in the world. "

Lee Eun-suk, director of the National Cancer Center, said, "This technology will be a new milestone in the treatment of cancer as it is widely applied to a variety of clinical and research applications." Continued research and The development of the National Cancer Center will be a good example of industrialization and commercialization. He said.

[ad_2]
Source link